Market Overview

UPDATE: Deutsche Bank Raines PT to $45 on Medtronic Following Top-Line Beat

Related MDT
Medtronics Reports FDA Approval Of Capsurefix Novus MRI Surescane 5076 Full-Body Scanners
Medtronic Announces Commencement of Pivotal Study of First Predictive Low Glucose Mgmt Technology for People with Diabetes
JPM Denies Report of Second Hack Attack (Fox Business)

Deutsche Bank reiterated its Hold rating on Medtronic (NYSE: MDT) but increased its price target from $43 to $45.

Deutsche Bank noted, "Top line beats, but EPS in line; Maintain Hold. In F2Q13, Medtronic's sales grew 5% ex-FX driven by the successful launch and share gains in the drug-eluting stent business (which accounted for 1.6%-pts of growth). While sales were better, EPS was in-line with Consensus ($0.01 below our estimate) due mainly to lower gross margins. Medtronic managed the P&L noting it took one-time gains from selling treasuries and minority investments to help offset FX hedging losses. We maintain our Hold rating but we are slightly increasing our PT to $45 from $43 given the more stable top line performance in the quarter and expectations going forward."

Medtronic closed at $42.75 on Wednesday.

Latest Ratings for MDT

DateFirmActionFromTo
Sep 2014NeedhamInitiates Coverage onBuy
Sep 2014Bank of AmericaReinstatesBuy
Sep 2014Sterne AgeeInitiates Coverage onNeutral

View More Analyst Ratings for MDT
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Price Target Pre-Market Outlook Analyst Ratings

 

Related Articles (MDT)

Around the Web, We're Loving...

Get Benzinga's Newsletters